Psychedelic stock warrants have already produced some phenomenal gains for investors. Now a new series of 5-year warrants is trading.
Psychedelics
Texas Would Study Psilocybin And MDMA To Treat PTSD And Depression Under New Bill
A Texas lawmaker introduced a bill on Wednesday that would require the state to study the therapeutic potential of psilocybin, MDMA and ketamine in the treatment of certain mental health conditions.
264 Million Reasons Psychedelic Stocks Have More Room to Grow
There is big money to be made from psychedelic stocks and the companies planning to treat depression will be the winners.
MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds
MindMed inks a new partnership for drug development and expands its pipeline.
Countdown to Psychedelic Stock Rally, Part 2: Sector-Wide Catalysts
A number of potential sector-wide catalysts for psychedelic stocks are already present or rapidly approaching.
MINDCURE Announces Listing of Warrants
Mind Cure has listed the warrants for trading from its recent financing. Warrants are valid until February 10, 2026, at an exercise price of CAD$0.80.
Mind Cure Announces Closing of $23 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option
Mind Cure closes on a CAD$23 million bought deal financing, after the full over-allotment was exercised.
Iowa GOP Lawmaker Makes Another Push To Decriminalize Psilocybin Mushrooms
A Republican lawmaker in Iowa is taking another swing at reforming the state’s psychedelics laws, introducing a bill on Tuesday to remove psilocybin from the list of controlled substances.
Psychedelic Drug DMT To Be Trialed On Stroke Victims
Researchers are to begin trialing the use of the psychedelic drug DMT as a treatment for stroke patients, after preclinical studies on rats indicated that the substance could help the brain repair itself following injury.
Countdown to Psychedelic Stock Rally, Part 1: Individual Drivers
After a torrid rally near the end of 2020, psychedelic drug stocks have been in a holding pattern. Here is why lift-off could occur at any time.
Field Trip Health Ltd. Announces Official Opening of Psychedelic Research and Cultivation Facility in Jamaica
Field Trip opens a psychedelic research facility in Jamaica, in partnership with University of the West Indies.
Magic mushrooms: How long do they stay in your system?
Magic mushrooms, or “shrooms,” are a type of mushroom containing psilocybin, a hallucinogenic compound.
New nonprofit aims to advise on creation of Oregon’s psilocybin-assisted therapy system
The people who brought psilocybin-assisted therapy to Oregon have created a new nonprofit to make sure the spirit of the ballot measure is preserved as state officials turn the voter-approved initiative into official policy.
Canada: Is There Magic In Those Mushrooms? Protecting Psilocybin And Other Actives From Magic Mushrooms
A few years ago, with the legalization of cannabis in Canada and other countries, chemists rushed to isolate active compounds from the plant, synthesize new cannabinoid derivatives and formulate new preparations for the delivery of these active compounds
Self-admitted psychedelic use and association with psychedelic culture harm perceptions of researchers’ scientific integrity
Psychedelic researchers who admit to using the substances themselves tend to be viewed as having less integrity compared to their abstinent counterparts, according to new research that surveyed 952 individuals from the United States.